Comparison
Coenzyme Q10 vs MOTS-c
Side-by-side of Coenzyme Q10 and MOTS-c. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Coenzyme Q10
CoQ10 supplement guide: 100 to 300 mg/day dosing, ubiquinol vs ubiquinone absorption, Q-SYMBIO heart failure data, statin myalgia evidence.
MOTS-c
MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide. Preclinical signals for insulin sensitivity, exercise capacity, dosage notes.
Effects at a glance
Coenzyme Q10
- •Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- •Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- •Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- •Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- •Plasma CoQ10 falls 15-40% with chronic statin therapy
- •Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
MOTS-c
- •16-amino-acid peptide encoded in mitochondrial DNA (12S rRNA region); discovered 2015
- •Activates AMPK in skeletal muscle and liver; improves insulin sensitivity in rodent models
- •Circulating endogenous levels decline with age, motivating the longevity-restoration hypothesis
- •CohBar's MOTS-c analog CB4211 discontinued after phase 1b NASH readout did not meet endpoints
- •Anecdotal protocols use 5 to 10 mg subcutaneously 2 to 3 times weekly
- •Not on the WADA Prohibited List as of 2026; future scrutiny likely given exercise-mimetic mechanism
Side-by-side
| Attribute | Coenzyme Q10 | MOTS-c |
|---|---|---|
| Category | supplement | peptide |
| Also known as | CoQ10, ubiquinone, ubiquinol, Q10 | Mitochondrial Open Reading Frame of the Twelve S rRNA-c, MOTSc |
| Half-life (hr) ↗ | 34 | 0.5 |
| Typical dose (mg) ↗ | 200 | 5 |
| Dosing frequency | 1 to 3 times daily with a fat-containing meal | 2-3x weekly |
| Routes | oral | subcutaneous |
| Onset (hr) | 6 | 1 |
| Peak (hr) | 720 | 4 |
| Molecular weight | 863.36 | 1880.18 |
| Molecular formula | C59H90O4 | C82H132N22O25S2 |
| Mechanism | Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E. | Mitochondrial-derived peptide that activates AMPK in skeletal muscle and liver, improves insulin sensitivity, and translocates to the nucleus under metabolic stress to modulate nuclear gene expression in retrograde mitochondrial signaling. |
| Legal status | Dietary supplement (most jurisdictions); prescription cardiac medication in Japan | Not FDA approved; research-use-only grey market; not currently on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Not scheduled (research chemical) |
| Pregnancy | Limited safety data; precautionary use at standard doses | Insufficient data; not recommended |
| CAS | 303-98-0 | 1627580-64-6 |
| PubChem CID | 5281915 | 139599184 |
| Wikidata | Q140453 | Q24832108 |
Safety profile
Coenzyme Q10
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Contraindications
- active warfarin therapy without monitoring (modest interaction with INR)
Interactions
- warfarin: structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR(moderate)
- antihypertensives: additive blood pressure-lowering at high doses(minor)
- statins: statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy(minor)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
MOTS-c
Common side effects
- injection-site irritation
- transient fatigue
- headache (anecdotal)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical)
- severe hypoglycemia risk on concurrent insulin or sulfonylurea
Interactions
- insulin: additive insulin sensitization may increase hypoglycemia risk(moderate)
- metformin: both activate AMPK; theoretical additive metabolic effect, no controlled data(minor)
- sulfonylureas: increased hypoglycemia risk via additive insulin sensitization(moderate)
Which Should You Take?
Coenzyme Q10 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. MOTS-c is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Coenzyme Q10.
- → If your priority is energy and stamina, pick Coenzyme Q10.
- → If your priority is metabolic health and glucose control, pick MOTS-c.
- → If your priority is mitochondrial function, pick MOTS-c.
Edge case: If you want to avoid research-only / gray-market sourcing, Coenzyme Q10 is the more accessible choice.
Default choice: Coenzyme Q10. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for MOTS-c only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Coenzyme Q10 and MOTS-c?
Coenzyme Q10 and MOTS-c differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Coenzyme Q10 or MOTS-c?
Coenzyme Q10 half-life is 34 hours; MOTS-c half-life is 0.5 hours.
Can you stack Coenzyme Q10 with MOTS-c?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper